RhumbLine Advisers
OVID icon

RhumbLine Advisers’s Ovid Therapeutics OVID Stock Holding History

RhumbLine Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$454K Buy
182,215
+12,076
+7% +$31.6K ﹤0.01% 2790
2026
Q2 		$458K Buy
+170,139
New +$439K ﹤0.01% 2832
2025
Q2 		– Sell
-80,917
Closed -$25.2K – 4229
2025
Q1 		$25.2K Sell
80,917
-3,161
-4% -$1.94K ﹤0.01% 3705
2024
Q4 		$78.5K Buy
84,078
+15,355
+22% +$17.2K ﹤0.01% 3543
2024
Q3 		$81.1K Sell
68,723
-1,010
-1% -$1.06K ﹤0.01% 3571
2024
Q2 		$53.6K Sell
69,733
-12,851
-16% -$35.8K ﹤0.01% 3663
2024
Q1 		$252K Buy
82,584
+2,918
+4% +$9.8K ﹤0.01% 3066
2023
Q4 		$257K Sell
79,666
-3,125
-4% -$10.7K ﹤0.01% 3058
2023
Q3 		$318K Buy
82,791
+4,023
+5% +$14.5K ﹤0.01% 2900
2023
Q2 		$258K Buy
+78,768
New +$267K ﹤0.01% 3099
2021
Q2 		– Sell
-48,990
Closed -$197K – 3077
2021
Q1 		$197K Sell
48,990
-680
-1% -$2.26K ﹤0.01% 2835
2020
Q4 		$115K Buy
49,670
+3,390
+7% +$15.8K ﹤0.01% 2952
2020
Q3 		$266K Sell
46,280
-1,945
-4% -$13K ﹤0.01% 2566
2020
Q2 		$355K Buy
+48,225
New +$226K ﹤0.01% 2491
2019
Q2 		– Sell
-17,010
Closed -$30K – 3000
2019
Q1 		$30K Buy
17,010
+459
+3% +$1.15K ﹤0.01% 2930
2018
Q4 		$40K Buy
16,551
+5,310
+47% +$24.2K ﹤0.01% 2956
2018
Q3 		$64K Sell
11,241
-575
-5% -$4.36K ﹤0.01% 2899
2018
Q2 		$92K Buy
+11,816
New +$101K ﹤0.01% 2879

Other funds holding OVID

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

RhumbLine Advisers's OVID Position: Q3 2026 in Review

RhumbLine Advisers increased its Ovid Therapeutics (OVID) stake by 7.1% in Q3 2026, buying an estimated $31.6K and bringing the position to 182,215 shares worth $454K. The position accounts for ﹤0.01% of the portfolio, ranked #2790.

RhumbLine Advisers first reported a position in OVID in Q2 2018 and has held it in 18 quarters since. The position peaked at $458K in Q2 2026. 47 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • RhumbLine Advisers held 182,215 shares of Ovid Therapeutics worth $454K as of Q3 2026.
  • RhumbLine Advisers bought 12,076 Ovid Therapeutics shares in Q3 2026, an estimated $31.6K.
  • Ovid Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2790 holding.
  • RhumbLine Advisers first reported a position in Ovid Therapeutics in Q2 2018 and has held it in 18 quarters since.
  • RhumbLine Advisers's Ovid Therapeutics position peaked at $458K in Q2 2026.
  • 47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.